Go to content
UR Home

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†

van Rhijn, Bas W.G. ; Mertens, Laura S. ; Mayr, Roman ; Bostrom, Peter J. ; Real, Francisco X. ; Zwarthoff, Ellen C. ; Boormans, Joost L. ; Abas, Cheno ; van Leenders, Geert J.L.H. ; Götz, Stefanie ; Hippe, Katrin ; Bertz, Simone ; Neuzillet, Yann ; Sanders, Joyce ; Broeks, Annegien ; van der Heijden, Michiel S. ; Jewett, Michael A.S. ; Marquez, Mirari ; Stoehr, Robert ; Zlotta, Alexandre R. ; Eckstein, Markus ; Soorojebally, Yanish ; Roshani, Hossain ; Burger, Maximilian ; Otto, Wolfgang ; Radvanyi, François ; Sirab, Nanor ; Pouessel, Damien ; Wullich, Bernd ; van der Kwast, Theo H. ; Malats, Núria ; Hartmann, Arndt ; Allory, Yves ; Zuiverloon, Tahlita C.M.


Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer (BC). FGFR3 mutations are common in noninvasive BC and associated with favorable BC prognosis. Overexpression was reported in up to 40% of FGFR3 wild-type muscle-invasive BC. We analyzed FGFR3 mutations, FGFR3, and p53 protein expression and assessed their prognostic value in a cohort of 1000 chemotherapy-naive ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 4239

Dissertations: dissertationen@ur.de
0941 943 3904

Research data: daten@ur.de
0941 943 4239

Contact persons